GEP20186825B - Formulation comprising hypolipidemic agent - Google Patents

Formulation comprising hypolipidemic agent

Info

Publication number
GEP20186825B
GEP20186825B GEAP201714025A GEAP2017014025A GEP20186825B GE P20186825 B GEP20186825 B GE P20186825B GE AP201714025 A GEAP201714025 A GE AP201714025A GE AP2017014025 A GEAP2017014025 A GE AP2017014025A GE P20186825 B GEP20186825 B GE P20186825B
Authority
GE
Georgia
Prior art keywords
formulation
hypolipidemic agent
alkalinizer
compo
modifiers
Prior art date
Application number
GEAP201714025A
Other languages
English (en)
Inventor
Jitendre D Patel
Prakash Davadra
Snehal Patel
Shafiq Sheikh
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of GEP20186825B publication Critical patent/GEP20186825B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
GEAP201714025A 2013-07-25 2014-07-24 Formulation comprising hypolipidemic agent GEP20186825B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2470MU2013 IN2013MU02470A (enExample) 2013-07-25 2013-07-25

Publications (1)

Publication Number Publication Date
GEP20186825B true GEP20186825B (en) 2018-02-26

Family

ID=51787141

Family Applications (1)

Application Number Title Priority Date Filing Date
GEAP201714025A GEP20186825B (en) 2013-07-25 2014-07-24 Formulation comprising hypolipidemic agent

Country Status (22)

Country Link
US (2) US9610277B2 (enExample)
EP (1) EP3024446A1 (enExample)
JP (1) JP2016523895A (enExample)
KR (1) KR101786843B1 (enExample)
CN (1) CN105407873A (enExample)
AP (1) AP2015008876A0 (enExample)
AR (1) AR097067A1 (enExample)
AU (1) AU2014294548B2 (enExample)
BR (1) BR112015031878A2 (enExample)
CA (1) CA2917923A1 (enExample)
EA (1) EA201690072A1 (enExample)
GE (1) GEP20186825B (enExample)
HK (1) HK1219222A1 (enExample)
IN (1) IN2013MU02470A (enExample)
MA (1) MA38865A1 (enExample)
MX (1) MX374628B (enExample)
NZ (1) NZ714558A (enExample)
PH (1) PH12015502802A1 (enExample)
SG (1) SG11201509798PA (enExample)
TW (1) TW201545773A (enExample)
WO (1) WO2015011730A1 (enExample)
ZA (1) ZA201508682B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022187B1 (en) 2006-05-23 2011-03-16 Intel Corporation Millimeter-wave communication system for an indoor area
KR101733414B1 (ko) 2011-01-31 2017-05-10 카딜라 핼쓰캐어 리미티드 지방이상증의 치료
WO2014174524A1 (en) 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR101913830B1 (ko) * 2016-12-05 2018-10-31 주식회사 코쿤디자인 기능성 led 어셈블리를 이용한 디스플레이 장치
MX382765B (es) 2016-12-09 2025-03-13 Zydus Lifesciences Ltd Tratamiento para la colangitis biliar primaria.
WO2020165782A1 (en) * 2019-02-13 2020-08-20 Cadila Healthcare Limited Treatment for polycystic ovarian syndrome (pcos)
WO2020183379A1 (en) * 2019-03-11 2020-09-17 Cadila Healthcare Limited Novel salts, crystalline forms and premix of hypolipidemic agent

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
KR950702545A (ko) 1992-07-03 1995-07-29 데이빗 로버츠 약제로서의 헤테로시클릭 화합물(Heterocyclic compounds as pharmaceutical)
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
ES2164241T3 (es) 1995-04-28 2002-02-16 Daiichi Seiyaku Co Compuestos pentaciclicos.
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CN1208326C (zh) 1998-04-23 2005-06-29 雷迪实验室有限公司 杂环化合物及其在医药方面的应用、其制备方法及含有它们的药物组合物
CN100357281C (zh) 1998-05-27 2007-12-26 雷迪实验室有限公司 双环化合物、其制备方法和包含它们的药物组合物
EP1123297A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
AU6325599A (en) 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
CZ304346B6 (cs) 2000-01-19 2014-03-19 Cadila Healthcare Ltd. Substituovaný pyrrolový derivát s hypolipidemickou hypocholesteremickou aktivitou, způsob jeho přípravy a farmaceutický přípravek obsahující tyto sloučeniny
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
JP4745616B2 (ja) * 2003-02-26 2011-08-10 武田薬品工業株式会社 安定化されたイミダゾール誘導体含有医薬組成物、イミダゾール誘導体の安定化方法
WO2005031335A1 (ja) 2003-09-26 2005-04-07 Mitsubishi Rayon Co., Ltd. 電気泳動装置および電気泳動法並びにそれを用いた生体関連物質の検出方法
GEP20094679B (en) 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
ES2351365T3 (es) * 2006-02-22 2011-02-03 EISAI R&D MANAGEMENT CO., LTD. Composición farmacéutica estabilizada.
EP2018157A2 (en) 2006-04-26 2009-01-28 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
JP5424571B2 (ja) * 2007-04-12 2014-02-26 協和発酵キリン株式会社 トピラマート含有固形製剤
BR112012012815B8 (pt) 2009-11-26 2021-05-25 Genfit uso de um composto selecionado de 1-[4-metil-tio-fenil]-3-[3,5-dimetil-4-carbóxi-dimetil-metilóxi-fenil]prop-2-en-1-ona e ácido 2-[2,6-dimetil-4-[3-[4-(metil-tio)fenil]-3-oxo-propil]fenóxi]-2-metilpropanóico
WO2012051333A1 (en) * 2010-10-12 2012-04-19 The Johns Hopkins University Antitussive compositions comprising memantine
KR101733414B1 (ko) 2011-01-31 2017-05-10 카딜라 핼쓰캐어 리미티드 지방이상증의 치료
WO2014174524A1 (en) * 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
MX2015016403A (es) 2013-05-30 2016-04-11 Cadila Healthcare Ltd Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica.
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
MX371021B (es) 2013-08-29 2020-01-13 Cadila Healthcare Ltd Procedimiento para preparar saroglitazar o sus sales farmaceuticamente aceptables.
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives

Also Published As

Publication number Publication date
JP2016523895A (ja) 2016-08-12
US20160136131A1 (en) 2016-05-19
MX2015016971A (es) 2016-04-25
KR20160013150A (ko) 2016-02-03
EP3024446A1 (en) 2016-06-01
NZ714558A (en) 2017-02-24
CN105407873A (zh) 2016-03-16
SG11201509798PA (en) 2016-02-26
CA2917923A1 (en) 2015-01-29
EA201690072A1 (ru) 2016-06-30
WO2015011730A1 (en) 2015-01-29
HK1219222A1 (zh) 2017-03-31
AU2014294548B2 (en) 2017-08-10
US9610277B2 (en) 2017-04-04
TW201545773A (zh) 2015-12-16
US10098868B2 (en) 2018-10-16
ZA201508682B (en) 2017-03-29
BR112015031878A2 (pt) 2017-07-25
MA38865A1 (fr) 2017-12-29
AP2015008876A0 (en) 2015-11-30
PH12015502802A1 (en) 2016-03-14
AR097067A1 (es) 2016-02-17
IN2013MU02470A (enExample) 2015-06-26
AU2014294548A1 (en) 2015-12-17
KR101786843B1 (ko) 2017-10-18
US20170266158A1 (en) 2017-09-21
MX374628B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
GEP20186825B (en) Formulation comprising hypolipidemic agent
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
TN2016000081A1 (en) Aminoheteroaryl benzamides as kinase inhibitors
MX2015012432A (es) Inhibidores piridinicos de la cinasa cdk9.
MY189761A (en) Quinazoline derivatives used to treat hiv
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
PH12016500024A1 (en) Bromodomain inhibitor
MX363456B (es) Compuestos para tratar atrofia muscular espinal.
GEP201706725B (en) Compounds and compositions as inhibitors of mek
GEP201706691B (en) Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
GEP201606598B (en) Heteroaromatic compounds as dopamine d1 ligands
UA109661C2 (uk) Фармацевтична композиція співкристалів трамадолу і коксибів
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
GEP201706621B (en) Benzamides
UA115357C2 (uk) Похідні піридин-4-ілу
PH12015502589A1 (en) 4`-azido, 3`-deoxy-3`-fluoro substituted nucleoside derivatives
GEP201606566B (en) Isoxazolidine derivatives
MX2015008919A (es) Carboxamidas basadas en pirazolilo i como inhibidores del canal de calcio activado por liberacion de calcio (crac).
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
MX2015008912A (es) Carboxamidas basadas en pirazolilo ii como inhibidores del canal de calcio activado por liberacion de calcio (crac).